Market Place
Sourcing Support
DURECT Sells ALZET® Product to Lafayette Instrument for $17.5M
25 Nov 2024 //
PR NEWSWIRE
DURECT to Announce Q3 2024 Results & Business Update
06 Nov 2024 //
PR NEWSWIRE
Durect To Present Larsucosterol Data At The Liver Meeting 2024
17 Oct 2024 //
PR NEWSWIRE
Durect Corportion Announces Larsucosterol Phase 3 Trial Design
25 Sep 2024 //
PR NEWSWIRE
DURECT Corporation to Present at H.C. Wainwright Global Investment Conference
04 Sep 2024 //
PR NEWSWIRE
DURECT Corporation To Announce Q2 2024 Results And Provide Update
07 Aug 2024 //
PR NEWSWIRE
DURECT Gets FDA Breakthrough For Larsucosterol In Alcoholic Hepatitis
21 May 2024 //
PR NEWSWIRE
DURECT Reports Q1 2024 Results, Business Update
13 May 2024 //
PR NEWSWIRE
DURECT To Announce Q1 2024 Results, Business Update
07 May 2024 //
PR NEWSWIRE
DURECT To Present AHFIRM Alcoholic Hepatitis Phase 2b Data
30 Apr 2024 //
PR NEWSWIRE
DURECT Corporation Reports Fourth Quarter and Full Year 2023 Financial Results
27 Mar 2024 //
PR NEWSWIRE
DURECT and Charles River Enter into Collaboration Agreement for ALZET
04 Mar 2024 //
PR NEWSWIRE
DURECT to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference
07 Feb 2024 //
PR NEWSWIRE
DURECT Corporation Announces Results from Phase 2b Trial of Larsucosterol
07 Nov 2023 //
PR NEWSWIRE
DURECT Announces Last Patient Last Visit in Ph 2b AHFIRM Trial of Larsucosterol
07 Sep 2023 //
PR NEWSWIRE
DURECT Corporation Announces Presentations in Upcoming Investor Conferences
31 Aug 2023 //
PR NEWSWIRE
DURECT Corp Reports Second Quarter 2023 Financial Results and Business Update
09 Aug 2023 //
PR NEWSWIRE
DURECT Corporation to Announce Second Quarter 2023 Financial Results
03 Aug 2023 //
PR NEWSWIRE
DURECT Announces $15M Direct Offering Priced At-The-Market Under Nasdaq Rules
20 Jul 2023 //
PR NEWSWIRE
DURECT concludes patient enrolment in Phase IIb trial of AH therapy
08 Jun 2023 //
CLINICAL TRIALS ARENA
DURECT Completes Enrollment in Phase 2b AHFIRM Trial of Larsucosterol
07 Jun 2023 //
PR NEWSWIRE
DURECT Corporation Reports 1Q 2023 FYR and Business Update
08 May 2023 //
PR NEWSWIRE
DURECT to Participate in Fireside Chat at the H.C. Wainwright BioConnect
25 Apr 2023 //
PR NEWSWIRE
DURECT Corporation Announces Appointment of Gail Maderis as Chair of the Board
21 Mar 2023 //
PR NEWSWIRE
DURECT Fireside Chat at the Oppenheimer 33rd Annual Healthcare Conference
09 Mar 2023 //
PR NEWSWIRE
DURECT Reports Fourth Quarter and Full Year 2022 Financial Results
07 Mar 2023 //
PR NEWSWIRE
DURECT Corp to Announce Fourth Quarter and Full Year 2022 Financial Results
28 Feb 2023 //
PR NEWSWIRE
DURECT Announces $10M Registered Direct Offering of Common Stock and Warrants
03 Feb 2023 //
PR NEWSWIRE
DURECT Corporation Reports Third Quarter 2022 Financial Results
02 Nov 2022 //
PRNEWSWIRE
DURECT Corporation to Announce Third Quarter 2022 Financial Results
26 Oct 2022 //
PRNEWSWIRE
DURECT Reaches Enrollment Milestone in Phase 2b AHFIRM Trial
06 Oct 2022 //
PRNEWSWIRE
Innocoll and DURECT Announce U.S. launch of POSIMIR®
26 Sep 2022 //
PRNEWSWIRE
DURECT Corp to Present at the H.C. Wainwright Global Investment Conference
06 Sep 2022 //
PRNEWSWIRE
DURECT Corporation Reports Second Quarter 2022 Financial Results
04 Aug 2022 //
PRNEWSWIRE
DURECT Corporation to Announce Second Quarter 2022 Financial Results
27 Jul 2022 //
PRNEWSWIRE
DURECT Corporation Appoints Timothy M. Papp as Chief Financial Officer
05 Jul 2022 //
PRNEWSWIRE
DURECT Corporation Reports First Quarter 2022 Financial Results
04 May 2022 //
PRNEWSWIRE
DURECT Corporation to Announce Q1 2022 Financial Results
27 Apr 2022 //
PRNEWSWIRE
DURECT Corporation To Present at 2022 Cantor Fitzgerald ROD Summit
23 Mar 2022 //
PRNEWSWIRE
DURECT Corp Fireside Chat at the Oppenheimer 32nd Annual Healthcare Conference
09 Mar 2022 //
PRNEWSWIRE
DURECT Corp Doses 1st European Patient in Phase 2b AHFIRM Study of Larsucosterol
01 Mar 2022 //
PRNEWSWIRE
DURECT Corporation to Announce Q4 and Full Year 2021 Financial Results
28 Feb 2022 //
PRNEWSWIRE
DURECT Corporation Expands Board of Directors with Appointment of Peter Garcia
14 Dec 2021 //
BIOSPACE
Data Presentation Today at The Liver Meeting 2021Shows Increasing Hospital (AH)
13 Nov 2021 //
PRNEWSWIRE
DURECT doses first ex-US patient in phase 2b AHFIRM study
12 Nov 2021 //
PHARMABIZ
DURECTDoses First ex-U.S. Patient in Phase 2b AHFIRM Study of Larsucosterol
10 Nov 2021 //
PRNEWSWIRE
DURECT Corporation Reports Third Quarter 2021 Financial Results
02 Nov 2021 //
PRNEWSWIRE
DURECT Corporation Fireside Chat at the H.C. Wainwright 5th Annual NASH
07 Oct 2021 //
PRNEWSWIRE
DURECT Corporation Fireside Chat at the Cantor Fitzgerald Healthcare Conference
23 Sep 2021 //
PRNEWSWIRE
DURECT Corp Fireside Chat at the H.C. Wainwright Annual Investment Conference
07 Sep 2021 //
PRNEWSWIRE
DURECT Second Quarter 2021 Financial Results and Provide Business Update
22 Jul 2021 //
PRNEWSWIRE
DURECT Second Quarter 2021 Financial Results and Provide Business Update
22 Jul 2021 //
PRNEWSWIRE
DURECT Corp Presents Additional Clinical Data from DUR-928 Phase 1b Trial
23 Jun 2021 //
PRNEWSWIRE
DURECT Corporation to Present Additional Clinical Data from DUR-928 Studies
09 Jun 2021 //
PRNEWSWIRE
DURECT Corporation Announces First Quarter 2021 Financial Results
04 May 2021 //
PRNEWSWIRE
DURECT Corporation Announces Publication of DUR-928`s Mechanism of Action
09 Mar 2021 //
YAHOO
DURECT Announces U.S. FDA Approval of POSIMIR® For Post-Surgical Pain Reduction
02 Feb 2021 //
BIOSPACE
Durect`s non-opioid painkiller brushes aside checkered , gaining FDA approval
02 Feb 2021 //
ENDPTS
DURECT Announces First Patient Dosed in Phase 2b AHFIRM Study of DUR-928
25 Jan 2021 //
PRNEWSWIRE
DURECT Announces First Patient Dosed in Phase 2b AHFIRM Study of DUR-928
25 Jan 2021 //
PRNEWSWIRE
